Ketoconazole and MK-2866 Interaction: Monitor | Peptide Database

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss. ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss. Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%). 91% achieved near-normal blood sugar levels versus 42% with placebo. ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%. Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

Join others researching Propranolol — share findings, ask questions, and learn from real experiences Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) and one of the oldest and most widely prescribed drugs in its class. FDA-approved since 1967 and marketed as Inderal, it blocks both beta-1 receptors in the heart (reducing heart rate, contractility, and cardiac output) and beta-2 receptors in the bronchial and vascular smooth muscle. In the performance-enhancing drug community, propranolol serves two primary roles: managing elevated resting heart rate caused by compounds such as trenbolone and clenbuterol, and controlling performance anxiety or situational anxiety symptoms. Trenbolone is notorious for raising resting heart rate and causing nocturnal tachycardia, while clenbuterol directly stimulates beta-2 receptors to increase heart rate as part of its sympathomimetic action. Propranolol's non-selective beta blockade makes it effective against both mechanisms. Its rapid onset (within 30-60 minutes of oral dosing) and relatively short duration of action make it well-suited for as-needed use, though it can also be dosed regularly for sustained heart rate control throughout an AAS cycle. Propranolol competitively blocks both beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in the sinoatrial node and myocardium reduces heart rate (negative chronotropy), decreases the force of cardiac contraction (negative inotropy), and slows atrioventricular conduction (negative dromotropy). This directly counteracts the tachycardia induced by sympathomimetic compounds like clenbuterol and the unexplained heart rate elevation commonly reported with trenbolone use. Beta-2 blockade in peripheral vasculature contributes to a modest increase in peripheral vascular resistance initially, though chronic use leads to a net reduction in blood pressure through decreased cardiac output and suppression of renin release from the juxtaglomerular cells. Propranolol is highly lipophilic, readily crossing the blood-brain barrier, which accounts for its efficacy in managing anxiety symptoms, essential tremor, and the physical manifestations of sympathetic nervous system activation (tremor, palpitations, sweating). This central penetration also explains why propranolol is more effective for anxiety-related indications than hydrophilic beta blockers like atenolol. The drug undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2, resulting in variable bioavailability (approximately 25-35%).